AU2001288515A1 - Gem-substituted alpha v beta 3 integrin antagonists - Google Patents

Info

Publication number

AU2001288515A1

AU2001288515A1 AU2001288515A AU8851501A AU2001288515A1 AU 2001288515 A1 AU2001288515 A1 AU 2001288515A1 AU 2001288515 A AU2001288515 A AU 2001288515A AU 8851501 A AU8851501 A AU 8851501A AU 2001288515 A1 AU2001288515 A1 AU 2001288515A1

Authority

AU

Australia

Prior art keywords

phenyl

solution

alkyl

product

group

Prior art date

2000-08-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 239000005557 antagonist Substances 0.000 title description 20
• 102000008607 Integrin beta3 Human genes 0.000 title description 2
• 108010020950 Integrin beta3 Proteins 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims description 135
• 125000000217 alkyl group Chemical group 0.000 claims description 84
• -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims description 64
• 125000003118 aryl group Chemical group 0.000 claims description 57
• 238000000034 method Methods 0.000 claims description 47
• 125000003545 alkoxy group Chemical group 0.000 claims description 44
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 41
• 125000001072 heteroaryl group Chemical group 0.000 claims description 40
• 229910052717 sulfur Inorganic materials 0.000 claims description 37
• 125000001188 haloalkyl group Chemical group 0.000 claims description 35
• 229910052739 hydrogen Inorganic materials 0.000 claims description 35
• 108010044426 integrins Proteins 0.000 claims description 35
• 102000006495 integrins Human genes 0.000 claims description 35
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 34
• 229910052757 nitrogen Inorganic materials 0.000 claims description 34
• 206010028980 Neoplasm Diseases 0.000 claims description 32
• 229910052760 oxygen Inorganic materials 0.000 claims description 32
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 25
• 229920006395 saturated elastomer Polymers 0.000 claims description 24
• 125000000304 alkynyl group Chemical group 0.000 claims description 21
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
• 229910052736 halogen Inorganic materials 0.000 claims description 21
• 150000002367 halogens Chemical group 0.000 claims description 21
• 125000003342 alkenyl group Chemical group 0.000 claims description 20
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
• 238000011282 treatment Methods 0.000 claims description 20
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims description 18
• 125000002252 acyl group Chemical group 0.000 claims description 17
• 125000005842 heteroatom Chemical group 0.000 claims description 17
• 125000003282 alkyl amino group Chemical group 0.000 claims description 16
• 125000002950 monocyclic group Chemical group 0.000 claims description 16
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 125000001424 substituent group Chemical group 0.000 claims description 15
• 125000004001 thioalkyl group Chemical group 0.000 claims description 15
• 125000000623 heterocyclic group Chemical group 0.000 claims description 14
• 229940124530 sulfonamide Drugs 0.000 claims description 13
• 150000003456 sulfonamides Chemical class 0.000 claims description 13
• 206010027476 Metastases Diseases 0.000 claims description 12
• 230000033115 angiogenesis Effects 0.000 claims description 12
• 125000002619 bicyclic group Chemical group 0.000 claims description 12
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
• 230000004614 tumor growth Effects 0.000 claims description 12
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
• 239000002253 acid Substances 0.000 claims description 11
• 125000004442 acylamino group Chemical group 0.000 claims description 11
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
• 229910052799 carbon Inorganic materials 0.000 claims description 11
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
• 230000009401 metastasis Effects 0.000 claims description 11
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 11
• RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 11
• 208000001132 Osteoporosis Diseases 0.000 claims description 10
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
• 208000002780 macular degeneration Diseases 0.000 claims description 10
• 239000002246 antineoplastic agent Substances 0.000 claims description 9
• 229910002091 carbon monoxide Inorganic materials 0.000 claims description 9
• 125000004181 carboxyalkyl group Chemical group 0.000 claims description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
• 230000009826 neoplastic cell growth Effects 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 208000037803 restenosis Diseases 0.000 claims description 9
• 150000003457 sulfones Chemical class 0.000 claims description 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
• 241000124008 Mammalia Species 0.000 claims description 8
• 206010003246 arthritis Diseases 0.000 claims description 8
• 229940127089 cytotoxic agent Drugs 0.000 claims description 8
• 230000015590 smooth muscle cell migration Effects 0.000 claims description 8
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
• 208000017442 Retinal disease Diseases 0.000 claims description 7
• 206010038923 Retinopathy Diseases 0.000 claims description 7
• 150000001336 alkenes Chemical group 0.000 claims description 7
• 150000001345 alkine derivatives Chemical class 0.000 claims description 7
• 125000001769 aryl amino group Chemical group 0.000 claims description 7
• 125000004122 cyclic group Chemical group 0.000 claims description 7
• 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 claims description 7
• 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 7
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 6
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 6
• 150000003857 carboxamides Chemical class 0.000 claims description 6
• 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
• 125000004076 pyridyl group Chemical group 0.000 claims description 6
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims description 5
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 5
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
• 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 5
• 125000003368 amide group Chemical group 0.000 claims description 5
• 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
• 125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 5
• 125000004104 aryloxy group Chemical group 0.000 claims description 5
• 150000001602 bicycloalkyls Chemical group 0.000 claims description 5
• 125000005518 carboxamido group Chemical group 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims description 5
• 230000001404 mediated effect Effects 0.000 claims description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
• ZRBWTQPZRQGEIN-UHFFFAOYSA-N 2-[1-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]cyclopentyl]acetic acid Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CC1(CC(=O)O)CCCC1 ZRBWTQPZRQGEIN-UHFFFAOYSA-N 0.000 claims description 4
• YVHAIVPPUIZFBA-UHFFFAOYSA-N Cyclopentylacetic acid Chemical compound OC(=O)CC1CCCC1 YVHAIVPPUIZFBA-UHFFFAOYSA-N 0.000 claims description 4
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
• 125000000524 functional group Chemical group 0.000 claims description 4
• 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 4
• 125000005843 halogen group Chemical group 0.000 claims description 4
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
• ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 claims description 3
• XYNHCZVSWZBUJW-UHFFFAOYSA-N 2-[1-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]cyclobutyl]acetic acid Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CC1(CC(=O)O)CCC1 XYNHCZVSWZBUJW-UHFFFAOYSA-N 0.000 claims description 3
• XSIACEHQVMRQJN-UHFFFAOYSA-N 2-[1-acetyl-4-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]piperidin-4-yl]acetic acid Chemical compound C1CN(C(=O)C)CCC1(CC(O)=O)CC(C=C1)=CC=C1OCCCNC1=CC=CC=N1 XSIACEHQVMRQJN-UHFFFAOYSA-N 0.000 claims description 3
• KJOMHIMVRRBOKD-UHFFFAOYSA-N 2-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methylsulfonyl]acetic acid Chemical compound C1=CC(CS(=O)(=O)CC(=O)O)=CC=C1OCCCNC1=CC=CC=N1 KJOMHIMVRRBOKD-UHFFFAOYSA-N 0.000 claims description 3
• KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 3
• KGMWOJCHZPZNQZ-UHFFFAOYSA-N 3,3-dimethyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 KGMWOJCHZPZNQZ-UHFFFAOYSA-N 0.000 claims description 3
• QGIRZMVNVDLIKQ-UHFFFAOYSA-N 3-benzyl-3-methyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CC(CC(O)=O)(C)CC1=CC=CC=C1 QGIRZMVNVDLIKQ-UHFFFAOYSA-N 0.000 claims description 3
• WJSYFMVFTAGCMV-UHFFFAOYSA-N 3-methyl-3-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]pent-4-enoic acid Chemical compound C1=CC(CC(CC(O)=O)(C)C=C)=CC=C1OCCCNC1=CC=CC=N1 WJSYFMVFTAGCMV-UHFFFAOYSA-N 0.000 claims description 3
• FUYKZCRCKXFKSE-UHFFFAOYSA-N 4-[3-bromo-5-fluoro-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound BrC1=CC(CC(C)(CC(O)=O)C)=CC(F)=C1OCCCNC1=CC=CC=N1 FUYKZCRCKXFKSE-UHFFFAOYSA-N 0.000 claims description 3
• NTJFQSZAKYMUTQ-UHFFFAOYSA-N 4-[3-cyano-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound N#CC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 NTJFQSZAKYMUTQ-UHFFFAOYSA-N 0.000 claims description 3
• BDUHVVJDEXRYOF-UHFFFAOYSA-N 4-[3-ethynyl-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound C#CC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 BDUHVVJDEXRYOF-UHFFFAOYSA-N 0.000 claims description 3
• UOACMCWVCLVCAD-UHFFFAOYSA-N 4-[3-fluoro-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound FC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 UOACMCWVCLVCAD-UHFFFAOYSA-N 0.000 claims description 3
• KMERJFNZURFHFM-UHFFFAOYSA-N 4-[3-methoxy-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound COC1=CC(CC(C)(C)CC(O)=O)=CC=C1OCCCNC1=CC=CC=N1 KMERJFNZURFHFM-UHFFFAOYSA-N 0.000 claims description 3
• OAWZCVUGQMYXCB-UHFFFAOYSA-N 4-[4-[2-(6-aminopyridin-2-yl)ethoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound C1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCC1=CC=CC(N)=N1 OAWZCVUGQMYXCB-UHFFFAOYSA-N 0.000 claims description 3
• AVQDJEHPEYOWKK-UHFFFAOYSA-N 5-(3-carboxy-2,2-dimethylpropyl)-2-[3-(pyridin-2-ylamino)propoxy]benzoic acid Chemical compound OC(=O)C1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 AVQDJEHPEYOWKK-UHFFFAOYSA-N 0.000 claims description 3
• 229930194542 Keto Natural products 0.000 claims description 3
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
• 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 3
• 125000005038 alkynylalkyl group Chemical group 0.000 claims description 3
• 125000001246 bromo group Chemical group Br* 0.000 claims description 3
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
• 229910001873 dinitrogen Inorganic materials 0.000 claims description 3
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
• 125000001153 fluoro group Chemical group F* 0.000 claims description 3
• 150000002431 hydrogen Chemical class 0.000 claims description 3
• 125000000468 ketone group Chemical group 0.000 claims description 3
• 150000002596 lactones Chemical class 0.000 claims description 3
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 3
• 150000003568 thioethers Chemical group 0.000 claims description 3
• BKIVZWFPVJBFIM-UHFFFAOYSA-N 2-[1-[2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]ethyl]cyclopentyl]acetic acid Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CCC1(CC(=O)O)CCCC1 BKIVZWFPVJBFIM-UHFFFAOYSA-N 0.000 claims description 2
• RMKCCAWNOBHOKM-UHFFFAOYSA-N 2-[1-acetyl-3-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]piperidin-3-yl]acetic acid Chemical compound C1N(C(=O)C)CCCC1(CC(O)=O)CC(C=C1)=CC=C1OCCCNC1=CC=CC=N1 RMKCCAWNOBHOKM-UHFFFAOYSA-N 0.000 claims description 2
• CXKIDZGPOXBDAO-UHFFFAOYSA-N 2-[[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methylsulfonyl]acetic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CS(=O)(=O)CC(O)=O)=CC=2)=N1 CXKIDZGPOXBDAO-UHFFFAOYSA-N 0.000 claims description 2
• UBWUSZNNSDZPBG-UHFFFAOYSA-N 3,3-dimethyl-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid Chemical compound C1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCC1=CC=C(CCCN2)C2=N1 UBWUSZNNSDZPBG-UHFFFAOYSA-N 0.000 claims description 2
• SAJQLKDAKITQMK-UHFFFAOYSA-N 4-N-(1,3-oxazol-2-yl)-2-N-pyrimidin-2-yl-3-N-(1,3-thiazol-2-yl)quinoline-2,3,4-triamine Chemical compound N=1C=CSC=1NC=1C(NC=2N=CC=CN=2)=NC2=CC=CC=C2C=1NC1=NC=CO1 SAJQLKDAKITQMK-UHFFFAOYSA-N 0.000 claims description 2
• VITTYGWUOFXKLZ-UHFFFAOYSA-N 4-[2-bromo-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound C1=C(Br)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 VITTYGWUOFXKLZ-UHFFFAOYSA-N 0.000 claims description 2
• BPUDQESXCYUUIZ-UHFFFAOYSA-N 4-[2-cyano-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound C1=C(C#N)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 BPUDQESXCYUUIZ-UHFFFAOYSA-N 0.000 claims description 2
• HCWTVUOVODBGBH-UHFFFAOYSA-N 4-[2-ethynyl-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound C1=C(C#C)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 HCWTVUOVODBGBH-UHFFFAOYSA-N 0.000 claims description 2
• IZDGOARRQXXAQG-UHFFFAOYSA-N 4-[3-chloro-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound ClC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 IZDGOARRQXXAQG-UHFFFAOYSA-N 0.000 claims description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
• GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims description 2
• MJXJXQKLVRNBTF-UHFFFAOYSA-N N-(1H-imidazol-2-yl)-2-morpholin-4-ylpyridin-3-amine Chemical compound C1COCCN1C1=NC=CC=C1NC1=NC=CN1 MJXJXQKLVRNBTF-UHFFFAOYSA-N 0.000 claims description 2
• 125000006524 alkoxy alkyl amino group Chemical group 0.000 claims description 2
• 150000003973 alkyl amines Chemical class 0.000 claims description 2
• 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
• 125000005265 dialkylamine group Chemical group 0.000 claims description 2
• LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 2
• SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical group NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 2
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims 21
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
• 125000004992 haloalkylamino group Chemical group 0.000 claims 1
• 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 508
• 239000000047 product Substances 0.000 description 275
• 239000000243 solution Substances 0.000 description 274
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 243
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 228
• 235000019439 ethyl acetate Nutrition 0.000 description 177
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 154
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 153
• 229940093499 ethyl acetate Drugs 0.000 description 153
• 238000006243 chemical reaction Methods 0.000 description 152
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 143
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 123
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 120
• 239000000203 mixture Substances 0.000 description 119
• 229910001868 water Inorganic materials 0.000 description 118
• 239000003921 oil Substances 0.000 description 92
• 235000019198 oils Nutrition 0.000 description 92
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 87
• 239000000741 silica gel Substances 0.000 description 74
• 229910002027 silica gel Inorganic materials 0.000 description 74
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 65
• 150000003254 radicals Chemical class 0.000 description 65
• 239000011541 reaction mixture Substances 0.000 description 62
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 60
• 238000004587 chromatography analysis Methods 0.000 description 59
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 54
• 239000012267 brine Substances 0.000 description 53
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 53
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 50
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 49
• 235000019441 ethanol Nutrition 0.000 description 48
• 238000005160 1H NMR spectroscopy Methods 0.000 description 46
• 239000002904 solvent Substances 0.000 description 45
• KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 43
• 239000012044 organic layer Substances 0.000 description 42
• 239000011734 sodium Substances 0.000 description 42
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 41
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 40
• 239000010410 layer Substances 0.000 description 39
• 239000000706 filtrate Substances 0.000 description 37
• 239000012043 crude product Substances 0.000 description 36
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 33
• 230000002829 reductive effect Effects 0.000 description 32
• 239000000284 extract Substances 0.000 description 31
• 238000010992 reflux Methods 0.000 description 31
• 239000007787 solid Substances 0.000 description 31
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 30
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 25
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 24
• 229960000583 acetic acid Drugs 0.000 description 23
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 22
• 239000012230 colorless oil Substances 0.000 description 22
• 238000005481 NMR spectroscopy Methods 0.000 description 21
• 238000003818 flash chromatography Methods 0.000 description 20
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 19
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 19
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
• 238000004128 high performance liquid chromatography Methods 0.000 description 18
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 16
• 238000003556 assay Methods 0.000 description 16
• 125000004404 heteroalkyl group Chemical group 0.000 description 16
• 229960004592 isopropanol Drugs 0.000 description 16
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 16
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• 229910052681 coesite Inorganic materials 0.000 description 15
• 229910052906 cristobalite Inorganic materials 0.000 description 15
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 15
• 239000007788 liquid Substances 0.000 description 15
• 229910052682 stishovite Inorganic materials 0.000 description 15
• 229910052905 tridymite Inorganic materials 0.000 description 15
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
• 229910052786 argon Inorganic materials 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 14
• 239000012047 saturated solution Substances 0.000 description 14
• 239000003656 tris buffered saline Substances 0.000 description 14
• 238000000746 purification Methods 0.000 description 13
• 235000002639 sodium chloride Nutrition 0.000 description 13
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
• 125000004429 atom Chemical group 0.000 description 12
• 210000004027 cell Anatomy 0.000 description 12
• 102000005962 receptors Human genes 0.000 description 12
• 108020003175 receptors Proteins 0.000 description 12
• 238000004809 thin layer chromatography Methods 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 11
• 239000000543 intermediate Substances 0.000 description 11
• 239000000463 material Substances 0.000 description 11
• 239000012299 nitrogen atmosphere Substances 0.000 description 11
• 238000004007 reversed phase HPLC Methods 0.000 description 11
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
• 125000002947 alkylene group Chemical group 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 10
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
• MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 9
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
• 239000012298 atmosphere Substances 0.000 description 9
• 229910000027 potassium carbonate Inorganic materials 0.000 description 9
• 238000003756 stirring Methods 0.000 description 9
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
• UBQKLVRIDJPLPF-UHFFFAOYSA-N OCCCNC1=CC=CC=[N+]1[O-] Chemical compound OCCCNC1=CC=CC=[N+]1[O-] UBQKLVRIDJPLPF-UHFFFAOYSA-N 0.000 description 8
• 108010031318 Vitronectin Proteins 0.000 description 8
• 102100035140 Vitronectin Human genes 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 239000003054 catalyst Substances 0.000 description 8
• 239000003480 eluent Substances 0.000 description 8
• 238000001819 mass spectrum Methods 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 229910001961 silver nitrate Inorganic materials 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 7
• 241000282414 Homo sapiens Species 0.000 description 7
• 235000019270 ammonium chloride Nutrition 0.000 description 7
• 239000007864 aqueous solution Substances 0.000 description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 238000001914 filtration Methods 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 6
• 235000011114 ammonium hydroxide Nutrition 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
• 239000012362 glacial acetic acid Substances 0.000 description 6
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• 208000006386 Bone Resorption Diseases 0.000 description 5
• 239000004215 Carbon black (E152) Substances 0.000 description 5
• 206010012689 Diabetic retinopathy Diseases 0.000 description 5
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
• 208000010191 Osteitis Deformans Diseases 0.000 description 5
• 208000027868 Paget disease Diseases 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 239000000908 ammonium hydroxide Substances 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 230000024279 bone resorption Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
• 239000008240 homogeneous mixture Substances 0.000 description 5
• 229930195733 hydrocarbon Natural products 0.000 description 5
• 238000005984 hydrogenation reaction Methods 0.000 description 5
• 208000027202 mammary Paget disease Diseases 0.000 description 5
• 208000028169 periodontal disease Diseases 0.000 description 5
• 239000008177 pharmaceutical agent Substances 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 5
• WYSRTEVFLQJJDN-UHFFFAOYSA-N 2-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1Cl WYSRTEVFLQJJDN-UHFFFAOYSA-N 0.000 description 4
• 102000000844 Cell Surface Receptors Human genes 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
• AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
• LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000003042 antagnostic effect Effects 0.000 description 4
• 230000001745 anti-biotin effect Effects 0.000 description 4
• 239000006286 aqueous extract Substances 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
• ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 4
• 238000004949 mass spectrometry Methods 0.000 description 4
• 239000002808 molecular sieve Substances 0.000 description 4
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 235000011007 phosphoric acid Nutrition 0.000 description 4
• 210000002381 plasma Anatomy 0.000 description 4
• 210000004623 platelet-rich plasma Anatomy 0.000 description 4
• 235000011181 potassium carbonates Nutrition 0.000 description 4
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
• 229910000029 sodium carbonate Inorganic materials 0.000 description 4
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 239000011593 sulfur Chemical group 0.000 description 4
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 230000005747 tumor angiogenesis Effects 0.000 description 4
• 239000003039 volatile agent Substances 0.000 description 4
• WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
• MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 3
• UYQPSKUPEXAQRJ-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylmethoxybenzene Chemical compound C1=CC(CCl)=CC=C1OCC1=CC=CC=C1 UYQPSKUPEXAQRJ-UHFFFAOYSA-N 0.000 description 3
• MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• MGJIWNQOCFCSHI-UHFFFAOYSA-N C=1C=C(OCCCNC=2[N+](=CC=CC=2)[O-])C=CC=1CC(C)(CC(=O)OCC)CC1=CC=CC=C1 Chemical compound C=1C=C(OCCCNC=2[N+](=CC=CC=2)[O-])C=CC=1CC(C)(CC(=O)OCC)CC1=CC=CC=C1 MGJIWNQOCFCSHI-UHFFFAOYSA-N 0.000 description 3
• 108010012088 Fibrinogen Receptors Proteins 0.000 description 3
• 102100022337 Integrin alpha-V Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 230000008485 antagonism Effects 0.000 description 3
• 239000003443 antiviral agent Substances 0.000 description 3
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000021164 cell adhesion Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 238000006392 deoxygenation reaction Methods 0.000 description 3
• 229960004132 diethyl ether Drugs 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 238000000921 elemental analysis Methods 0.000 description 3
• IPHYKENBQBGSOX-UHFFFAOYSA-N ethyl 3-benzyl-2-cyano-4-(4-methoxyphenyl)-3-methylbutanoate Chemical compound C=1C=C(OC)C=CC=1CC(C)(C(C#N)C(=O)OCC)CC1=CC=CC=C1 IPHYKENBQBGSOX-UHFFFAOYSA-N 0.000 description 3
• GBVYIZKXGUULPW-UHFFFAOYSA-N ethyl 3-benzyl-3-methyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoate Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CC(C)(CC(=O)OCC)CC1=CC=CC=C1 GBVYIZKXGUULPW-UHFFFAOYSA-N 0.000 description 3
• PKHGCVDFRPXVNA-UHFFFAOYSA-N ethyl 3-benzyl-4-(4-hydroxyphenyl)-3-methylbutanoate Chemical compound C=1C=C(O)C=CC=1CC(C)(CC(=O)OCC)CC1=CC=CC=C1 PKHGCVDFRPXVNA-UHFFFAOYSA-N 0.000 description 3
• ZBPRTJVDHGPJTI-UHFFFAOYSA-N ethyl 3-benzyl-4-(4-methoxyphenyl)-3-methylbutanoate Chemical compound C=1C=C(OC)C=CC=1CC(C)(CC(=O)OCC)CC1=CC=CC=C1 ZBPRTJVDHGPJTI-UHFFFAOYSA-N 0.000 description 3
• WRIIMCPFIUMULV-UHFFFAOYSA-N ethyl 4-[2-bromo-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoate Chemical compound C1=C(Br)C(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=N1 WRIIMCPFIUMULV-UHFFFAOYSA-N 0.000 description 3
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 210000002997 osteoclast Anatomy 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
• UUVJAGTYIVYFOS-UHFFFAOYSA-N (3-fluoro-4-methylphenyl)methanol Chemical compound CC1=CC=C(CO)C=C1F UUVJAGTYIVYFOS-UHFFFAOYSA-N 0.000 description 2
• HGFOOLONGOBCMP-IBGZPJMESA-N (3s)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical class C1=NC(OC)=CC=C1[C@H](CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-IBGZPJMESA-N 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• WFWKNGZODAOLEO-UHFFFAOYSA-N 1-(4-Methoxyphenyl)-2-propanone Chemical compound COC1=CC=C(CC(C)=O)C=C1 WFWKNGZODAOLEO-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
• LZYZWYOPJANCRQ-UHFFFAOYSA-N 2-[1-[2-oxo-2-[4-[2-(pyridin-2-ylamino)ethoxy]phenyl]ethyl]cyclopentyl]acetic acid Chemical compound C=1C=C(OCCNC=2N=CC=CC=2)C=CC=1C(=O)CC1(CC(=O)O)CCCC1 LZYZWYOPJANCRQ-UHFFFAOYSA-N 0.000 description 2
• ZYDMKCSBAHXNSP-UHFFFAOYSA-N 2-[1-[2-oxo-2-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]ethyl]cyclopentyl]acetic acid Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1C(=O)CC1(CC(=O)O)CCCC1 ZYDMKCSBAHXNSP-UHFFFAOYSA-N 0.000 description 2
• ZNHQWIUVDRRBOV-UHFFFAOYSA-N 2-bromo-1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C(Br)=C1 ZNHQWIUVDRRBOV-UHFFFAOYSA-N 0.000 description 2
• 150000005749 2-halopyridines Chemical class 0.000 description 2
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• GVBFACUKFNOIQP-UHFFFAOYSA-N 3-(2-bromo-4-methoxyphenyl)-2,2-dimethylpropanal Chemical compound COC1=CC=C(CC(C)(C)C=O)C(Br)=C1 GVBFACUKFNOIQP-UHFFFAOYSA-N 0.000 description 2
• YEEFCVCUYKRSFC-UHFFFAOYSA-N 3-(3-fluoro-4-methylphenyl)-2,2-dimethylpropanal Chemical compound CC1=CC=C(CC(C)(C)C=O)C=C1F YEEFCVCUYKRSFC-UHFFFAOYSA-N 0.000 description 2
• RUCJCNYUGIDSER-UHFFFAOYSA-N 3-[[2-[5-(hydrazinylmethylideneamino)pentanoylamino]acetyl]amino]-3-pyridin-3-ylpropanoic acid Chemical compound NN=CNCCCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=CN=C1 RUCJCNYUGIDSER-UHFFFAOYSA-N 0.000 description 2
• NMZPABLXAUWGLQ-UHFFFAOYSA-N 3-benzyl-4-(4-methoxyphenyl)-3-methylbutanoic acid Chemical compound C1=CC(OC)=CC=C1CC(C)(CC(O)=O)CC1=CC=CC=C1 NMZPABLXAUWGLQ-UHFFFAOYSA-N 0.000 description 2
• SOQCZBSZZLWDGU-UHFFFAOYSA-N 3-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1F SOQCZBSZZLWDGU-UHFFFAOYSA-N 0.000 description 2
• VZXOSPWVNCTRDZ-UHFFFAOYSA-N 3-methyl-3-pyridin-3-yl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C=1C=CN=CC=1C(CC(O)=O)(C)CC(C=C1)=CC=C1OCCCNC1=CC=CC=N1 VZXOSPWVNCTRDZ-UHFFFAOYSA-N 0.000 description 2
• WADCGGGQNLRPFT-UHFFFAOYSA-N 4-(2-bromo-4-methoxyphenyl)-3,3-dimethylbutanal Chemical compound COC1=CC=C(CC(C)(C)CC=O)C(Br)=C1 WADCGGGQNLRPFT-UHFFFAOYSA-N 0.000 description 2
• CDFRDDZQCBOCGF-UHFFFAOYSA-N 4-(chloromethyl)-2-fluoro-1-methylbenzene Chemical compound CC1=CC=C(CCl)C=C1F CDFRDDZQCBOCGF-UHFFFAOYSA-N 0.000 description 2
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
• UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 229940123038 Integrin antagonist Drugs 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
• FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 238000006751 Mitsunobu reaction Methods 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 102000019997 adhesion receptor Human genes 0.000 description 2
• 108010013985 adhesion receptor Proteins 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 125000005360 alkyl sulfoxide group Chemical group 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 150000005840 aryl radicals Chemical class 0.000 description 2
• 125000005362 aryl sulfone group Chemical group 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 125000005604 azodicarboxylate group Chemical group 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000004709 cell invasion Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 239000007979 citrate buffer Substances 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000013058 crude material Substances 0.000 description 2
• XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 125000004663 dialkyl amino group Chemical group 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000012039 electrophile Substances 0.000 description 2
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000004023 fresh frozen plasma Substances 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
• 238000004896 high resolution mass spectrometry Methods 0.000 description 2
• 229940106780 human fibrinogen Drugs 0.000 description 2
• 150000004678 hydrides Chemical class 0.000 description 2
• 150000001261 hydroxy acids Chemical class 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• RBWRWAUAVRMBAC-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=[C-]C=C1 RBWRWAUAVRMBAC-UHFFFAOYSA-M 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 150000003833 nucleoside derivatives Chemical class 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000011736 potassium bicarbonate Substances 0.000 description 2
• 235000015497 potassium bicarbonate Nutrition 0.000 description 2
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 239000011698 potassium fluoride Substances 0.000 description 2
• 229910000105 potassium hydride Inorganic materials 0.000 description 2
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
• VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 238000004659 sterilization and disinfection Methods 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
• VZPRWWONPMXDGF-UHFFFAOYSA-N tert-butyl n-[6-(2-hydroxyethyl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(CCO)=N1 VZPRWWONPMXDGF-UHFFFAOYSA-N 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229910052727 yttrium Inorganic materials 0.000 description 2
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
• PDBXFVPMVYQICB-UHFFFAOYSA-N (3-methoxy-4-phenylmethoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC=C1OCC1=CC=CC=C1 PDBXFVPMVYQICB-UHFFFAOYSA-N 0.000 description 1
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
• BTTUMVHWIAXYPJ-UHFFFAOYSA-N 1,3-dithian-2-yl(trimethyl)silane Chemical compound C[Si](C)(C)C1SCCCS1 BTTUMVHWIAXYPJ-UHFFFAOYSA-N 0.000 description 1
• IKFGSOJYHVTNDV-UHFFFAOYSA-N 1-(4-phenylmethoxyphenyl)propan-1-one Chemical compound C1=CC(C(=O)CC)=CC=C1OCC1=CC=CC=C1 IKFGSOJYHVTNDV-UHFFFAOYSA-N 0.000 description 1
• BQEZDRYGCALAIA-UHFFFAOYSA-N 1-acetyl-3-[(4-methylphenyl)methyl]piperidine-3-carbaldehyde Chemical compound C1N(C(=O)C)CCCC1(C=O)CC1=CC=C(C)C=C1 BQEZDRYGCALAIA-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical group O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• UFZJFFPZRWDKHJ-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 3-[(4-methylphenyl)methyl]piperidine-1,3-dicarboxylate Chemical compound C=1C=C(C)C=CC=1CC1(C(=O)OCC)CCCN(C(=O)OC(C)(C)C)C1 UFZJFFPZRWDKHJ-UHFFFAOYSA-N 0.000 description 1
• YCXCRFGBFZTUSU-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl piperidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 YCXCRFGBFZTUSU-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• DIKLONWZAOPACX-UHFFFAOYSA-N 2,2-dimethyl-3-(4-phenylmethoxyphenyl)propanal Chemical compound C1=CC(CC(C)(C)C=O)=CC=C1OCC1=CC=CC=C1 DIKLONWZAOPACX-UHFFFAOYSA-N 0.000 description 1
• WEMUNMQFXOILNO-UHFFFAOYSA-N 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol Chemical compound C1CCNC2=NC(CCO)=CC=C21 WEMUNMQFXOILNO-UHFFFAOYSA-N 0.000 description 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
• DCFVBCLAHYGEII-UHFFFAOYSA-N 2-[1-acetyl-3-[(4-methylphenyl)methyl]piperidin-3-yl]acetaldehyde Chemical compound C1N(C(=O)C)CCCC1(CC=O)CC1=CC=C(C)C=C1 DCFVBCLAHYGEII-UHFFFAOYSA-N 0.000 description 1
• MDBOJVDNPUCLGS-UHFFFAOYSA-N 2-[2,2-dimethyl-3-(4-phenylmethoxyphenyl)propylidene]-1,3-dithiane Chemical compound S1CCCSC1=CC(C)(C)CC(C=C1)=CC=C1OCC1=CC=CC=C1 MDBOJVDNPUCLGS-UHFFFAOYSA-N 0.000 description 1
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
• AHIGENQUNLGJLS-UHFFFAOYSA-N 2-methyl-3-(4-methylphenyl)-2-pyridin-3-ylpropan-1-ol Chemical compound C1=CC(C)=CC=C1CC(C)(CO)C1=CC=CN=C1 AHIGENQUNLGJLS-UHFFFAOYSA-N 0.000 description 1
• PONKXRXXYQBRSD-UHFFFAOYSA-N 2-methyl-3-(4-methylphenyl)-2-pyridin-3-ylpropanal Chemical compound C1=CC(C)=CC=C1CC(C)(C=O)C1=CC=CN=C1 PONKXRXXYQBRSD-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• SINYIYVCAWAMNW-UHFFFAOYSA-N 3,3-dimethyl-4-(4-phenylmethoxyphenyl)butanoic acid Chemical compound C1=CC(CC(C)(CC(O)=O)C)=CC=C1OCC1=CC=CC=C1 SINYIYVCAWAMNW-UHFFFAOYSA-N 0.000 description 1
• CFQCUWPAVGKHKO-UHFFFAOYSA-N 3,3-dimethyl-4-[2-(2-phenylethynyl)-4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C1=C(C#CC=2C=CC=CC=2)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 CFQCUWPAVGKHKO-UHFFFAOYSA-N 0.000 description 1
• NFSJPEXTDIFODE-UHFFFAOYSA-N 3,3-dimethyl-4-[2-(2-phenylethynyl)-4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C#CC=2C=CC=CC=2)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 NFSJPEXTDIFODE-UHFFFAOYSA-N 0.000 description 1
• UHLCWLMESMWNHO-UHFFFAOYSA-N 3,3-dimethyl-4-[4-[2-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(CCOC=2C=CC(CC(C)(C)CC(O)=O)=CC=2)=N1 UHLCWLMESMWNHO-UHFFFAOYSA-N 0.000 description 1
• WNHPMKYMPWMAIT-UHFFFAOYSA-N 3,4,5,6-tetrahydro-2h-azepine Chemical compound C1CCC=NCC1 WNHPMKYMPWMAIT-UHFFFAOYSA-N 0.000 description 1
• CBBVKUVVHMPIFN-UHFFFAOYSA-N 3-(2,5-dibromo-4-hydroxy-3-methoxyphenyl)-2,2-dimethylpropanal Chemical compound COC1=C(O)C(Br)=CC(CC(C)(C)C=O)=C1Br CBBVKUVVHMPIFN-UHFFFAOYSA-N 0.000 description 1
• AVHOFNSHBKJBJE-UHFFFAOYSA-N 3-(3-methoxy-4-phenylmethoxyphenyl)-2,2-dimethylpropanal Chemical compound COC1=CC(CC(C)(C)C=O)=CC=C1OCC1=CC=CC=C1 AVHOFNSHBKJBJE-UHFFFAOYSA-N 0.000 description 1
• HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• ISGQBPUFIQJUAB-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-3-methylpent-4-enoic acid Chemical compound COC1=CC=C(CC(C)(CC(O)=O)C=C)C=C1 ISGQBPUFIQJUAB-UHFFFAOYSA-N 0.000 description 1
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
• AGMZSYQMSHMXLT-UHFFFAOYSA-N 3-aminobutan-1-ol Chemical compound CC(N)CCO AGMZSYQMSHMXLT-UHFFFAOYSA-N 0.000 description 1
• YZXIAKMLEHKWOY-UHFFFAOYSA-N 3-methyl-4-(4-methylphenyl)-3-pyridin-3-ylbutanal Chemical compound C1=CC(C)=CC=C1CC(C)(CC=O)C1=CC=CN=C1 YZXIAKMLEHKWOY-UHFFFAOYSA-N 0.000 description 1
• LBEBBIWZIGURQJ-UHFFFAOYSA-N 3-methyl-4-oxo-4-(4-phenylmethoxyphenyl)butanoic acid Chemical compound C1=CC(C(=O)C(CC(O)=O)C)=CC=C1OCC1=CC=CC=C1 LBEBBIWZIGURQJ-UHFFFAOYSA-N 0.000 description 1
• FJABWQVTKBPJSJ-UHFFFAOYSA-N 4-(3-fluoro-4-methylphenyl)-3,3-dimethylbutanal Chemical compound CC1=CC=C(CC(C)(C)CC=O)C=C1F FJABWQVTKBPJSJ-UHFFFAOYSA-N 0.000 description 1
• RWYQBTIHSCUXJR-UHFFFAOYSA-N 4-(chloromethyl)-2-methoxy-1-phenylmethoxybenzene Chemical compound COC1=CC(CCl)=CC=C1OCC1=CC=CC=C1 RWYQBTIHSCUXJR-UHFFFAOYSA-N 0.000 description 1
• XNXCPUMZOZLYSN-UHFFFAOYSA-N 4-[2-bromo-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Br)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 XNXCPUMZOZLYSN-UHFFFAOYSA-N 0.000 description 1
• OMPNQEDTRZELGT-UHFFFAOYSA-N 4-[2-cyano-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C#N)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 OMPNQEDTRZELGT-UHFFFAOYSA-N 0.000 description 1
• RLQVBRUOZJKVCM-UHFFFAOYSA-N 4-[2-ethynyl-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C#C)C(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 RLQVBRUOZJKVCM-UHFFFAOYSA-N 0.000 description 1
• NUWKCAMXYJOTPQ-UHFFFAOYSA-N 4-[3-bromo-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid Chemical compound BrC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 NUWKCAMXYJOTPQ-UHFFFAOYSA-N 0.000 description 1
• KVLYFZYSRHYLMG-UHFFFAOYSA-N 4-[3-bromo-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoic acid;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.OC(=O)C(F)(F)F.BrC1=CC(CC(C)(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 KVLYFZYSRHYLMG-UHFFFAOYSA-N 0.000 description 1
• XDJAAZYHCCRJOK-UHFFFAOYSA-N 4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1 XDJAAZYHCCRJOK-UHFFFAOYSA-N 0.000 description 1
• XHPVOSNOIWGRQQ-UHFFFAOYSA-N 4-pyridin-2-ylmorpholine Chemical compound C1COCCN1C1=CC=CC=N1 XHPVOSNOIWGRQQ-UHFFFAOYSA-N 0.000 description 1
• QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• GFWLMILMVMCJDI-UHFFFAOYSA-N 8-oxaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)OC(=O)CC11CCCC1 GFWLMILMVMCJDI-UHFFFAOYSA-N 0.000 description 1
• MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 108010037003 Buserelin Proteins 0.000 description 1
• GVXVFFZGZCUFIA-UHFFFAOYSA-N C1=CC(CC(C)(C)CC(=O)OC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] Chemical compound C1=CC(CC(C)(C)CC(=O)OC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] GVXVFFZGZCUFIA-UHFFFAOYSA-N 0.000 description 1
• ABBZEHCILUXTGA-UHFFFAOYSA-N C=1C=C(OCCCNC=2[N+](=CC=CC=2)[O-])C=CC=1CC1(CC(=O)OCC)CCCN(C(C)=O)C1 Chemical compound C=1C=C(OCCCNC=2[N+](=CC=CC=2)[O-])C=CC=1CC1(CC(=O)OCC)CCCN(C(C)=O)C1 ABBZEHCILUXTGA-UHFFFAOYSA-N 0.000 description 1
• NGJDYDSTWPGBID-UHFFFAOYSA-N C=1C=CN=CC=1C(C)(CC(=O)OCC)CC(C=C1)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] Chemical compound C=1C=CN=CC=1C(C)(CC(=O)OCC)CC(C=C1)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] NGJDYDSTWPGBID-UHFFFAOYSA-N 0.000 description 1
• AKVNVOVCMMLGHW-UHFFFAOYSA-N COC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] Chemical compound COC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] AKVNVOVCMMLGHW-UHFFFAOYSA-N 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
• YEUQQZMNMISAGR-UHFFFAOYSA-N FC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] Chemical compound FC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=[N+]1[O-] YEUQQZMNMISAGR-UHFFFAOYSA-N 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010049088 Osteopenia Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000012641 Pigmentation disease Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 108010048673 Vitronectin Receptors Proteins 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 239000012670 alkaline solution Substances 0.000 description 1
• 125000004946 alkenylalkyl group Chemical group 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 150000001351 alkyl iodides Chemical class 0.000 description 1
• 150000008051 alkyl sulfates Chemical class 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 150000003927 aminopyridines Chemical class 0.000 description 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 101150044616 araC gene Proteins 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• AXSIIYFPGZWYLL-UHFFFAOYSA-N bis(propan-2-yloxycarbonyl)azaniumylideneazanide Chemical compound CC(C)OC(=O)[N+](=[N-])C(=O)OC(C)C AXSIIYFPGZWYLL-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229960004395 bleomycin sulfate Drugs 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 108010009896 bone resorption factor Proteins 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
• 235000008207 calcium folinate Nutrition 0.000 description 1
• 239000011687 calcium folinate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 229940111221 carmustine 100 mg Drugs 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 238000003352 cell adhesion assay Methods 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
• 229910000151 chromium(III) phosphate Inorganic materials 0.000 description 1
• IKZBVTPSNGOVRJ-UHFFFAOYSA-K chromium(iii) phosphate Chemical compound [Cr+3].[O-]P([O-])([O-])=O IKZBVTPSNGOVRJ-UHFFFAOYSA-K 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• CZZBXGOYISFHRY-UHFFFAOYSA-N copper;hydroiodide Chemical compound [Cu].I CZZBXGOYISFHRY-UHFFFAOYSA-N 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940034087 dacarbazine 100 mg Drugs 0.000 description 1
• 229940032356 dactinomycin 0.5 mg Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
• 125000006003 dichloroethyl group Chemical group 0.000 description 1
• 150000005690 diesters Chemical class 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• PWLLZZMFFZUSOG-UHFFFAOYSA-N dimethyl cyclopropane-1,1-dicarboxylate Chemical compound COC(=O)C1(C(=O)OC)CC1 PWLLZZMFFZUSOG-UHFFFAOYSA-N 0.000 description 1
• 150000002009 diols Chemical class 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960004766 estradiol valerate Drugs 0.000 description 1
• 229960003399 estrone Drugs 0.000 description 1
• 239000012259 ether extract Substances 0.000 description 1
• 229960002568 ethinylestradiol Drugs 0.000 description 1
• KKDXOKMYGIKBDD-SDNWHVSQSA-N ethyl (e)-2-cyano-4-(4-methoxyphenyl)-3-methylbut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/C)CC1=CC=C(OC)C=C1 KKDXOKMYGIKBDD-SDNWHVSQSA-N 0.000 description 1
• ZIQQJMDCEMDJJN-UHFFFAOYSA-N ethyl 2-(4-methoxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)C(C(C)(C)C)C1=CC=C(OC)C=C1 ZIQQJMDCEMDJJN-UHFFFAOYSA-N 0.000 description 1
• FOYNVNPGEAYZEM-UHFFFAOYSA-N ethyl 2-[1-acetyl-3-[(4-hydroxyphenyl)methyl]piperidin-3-yl]acetate Chemical compound C=1C=C(O)C=CC=1CC1(CC(=O)OCC)CCCN(C(C)=O)C1 FOYNVNPGEAYZEM-UHFFFAOYSA-N 0.000 description 1
• YGKQEFJLHDTTLM-UHFFFAOYSA-N ethyl 2-[1-acetyl-3-[(4-methylphenyl)methyl]piperidin-3-yl]acetate Chemical compound C=1C=C(C)C=CC=1CC1(CC(=O)OCC)CCCN(C(C)=O)C1 YGKQEFJLHDTTLM-UHFFFAOYSA-N 0.000 description 1
• GUXBDEDOPDRKLG-UHFFFAOYSA-N ethyl 2-[1-acetyl-3-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]piperidin-3-yl]acetate Chemical compound C=1C=C(OCCCNC=2N=CC=CC=2)C=CC=1CC1(CC(=O)OCC)CCCN(C(C)=O)C1 GUXBDEDOPDRKLG-UHFFFAOYSA-N 0.000 description 1
• JNDKQVMBTGEYSK-UHFFFAOYSA-N ethyl 2-cyano-3-[(4-methoxyphenyl)methyl]-3-methylpent-4-enoate Chemical compound CCOC(=O)C(C#N)C(C)(C=C)CC1=CC=C(OC)C=C1 JNDKQVMBTGEYSK-UHFFFAOYSA-N 0.000 description 1
• KKDXOKMYGIKBDD-UHFFFAOYSA-N ethyl 2-cyano-4-(4-methoxyphenyl)-3-methylbut-2-enoate Chemical compound CCOC(=O)C(C#N)=C(C)CC1=CC=C(OC)C=C1 KKDXOKMYGIKBDD-UHFFFAOYSA-N 0.000 description 1
• ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
• MAXXFVCNLFNSDH-UHFFFAOYSA-N ethyl 2-methyl-3-(4-methylphenyl)-2-pyridin-3-ylpropanoate Chemical compound C=1C=CN=CC=1C(C)(C(=O)OCC)CC1=CC=C(C)C=C1 MAXXFVCNLFNSDH-UHFFFAOYSA-N 0.000 description 1
• RPWXYCRIAGBAGY-UHFFFAOYSA-N ethyl 2-pyridin-3-ylacetate Chemical compound CCOC(=O)CC1=CC=CN=C1 RPWXYCRIAGBAGY-UHFFFAOYSA-N 0.000 description 1
• RPEUEJTZHRHZQD-UHFFFAOYSA-N ethyl 2-pyridin-3-ylpropanoate Chemical compound CCOC(=O)C(C)C1=CC=CN=C1 RPEUEJTZHRHZQD-UHFFFAOYSA-N 0.000 description 1
• CALLAJMBTFWAQC-UHFFFAOYSA-N ethyl 3,3-dimethyl-4-[2-(2-phenylethynyl)-4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoate Chemical compound C1=C(C#CC=2C=CC=CC=2)C(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=N1 CALLAJMBTFWAQC-UHFFFAOYSA-N 0.000 description 1
• FPTIECMLHHKIJO-UHFFFAOYSA-N ethyl 3-[(4-hydroxyphenyl)methyl]-3-methylpent-4-enoate Chemical compound CCOC(=O)CC(C)(C=C)CC1=CC=C(O)C=C1 FPTIECMLHHKIJO-UHFFFAOYSA-N 0.000 description 1
• MZIJITLBBGCXSF-UHFFFAOYSA-N ethyl 3-[(4-methoxyphenyl)methyl]-3-methylpent-4-enoate Chemical compound CCOC(=O)CC(C)(C=C)CC1=CC=C(OC)C=C1 MZIJITLBBGCXSF-UHFFFAOYSA-N 0.000 description 1
• RCQORGOSCIQINY-UHFFFAOYSA-N ethyl 3-[[4-[3-[(1-hydroxy-2h-pyridin-2-yl)amino]propoxy]phenyl]methyl]-3-methylpent-4-enoate Chemical compound C1=CC(CC(C)(CC(=O)OCC)C=C)=CC=C1OCCCNC1N(O)C=CC=C1 RCQORGOSCIQINY-UHFFFAOYSA-N 0.000 description 1
• UVNRFOXJWPIFOT-UHFFFAOYSA-N ethyl 3-methyl-3-[[4-[3-(pyridin-2-ylamino)propoxy]phenyl]methyl]pent-4-enoate Chemical compound C1=CC(CC(C)(CC(=O)OCC)C=C)=CC=C1OCCCNC1=CC=CC=N1 UVNRFOXJWPIFOT-UHFFFAOYSA-N 0.000 description 1
• WQFMRMGRQJHVPZ-UHFFFAOYSA-N ethyl 3-methyl-3-pyridin-3-yl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoate Chemical compound C=1C=CN=CC=1C(C)(CC(=O)OCC)CC(C=C1)=CC=C1OCCCNC1=CC=CC=N1 WQFMRMGRQJHVPZ-UHFFFAOYSA-N 0.000 description 1
• OPLFCBAQVUFSJL-UHFFFAOYSA-N ethyl 3-methyl-4-(4-methylphenyl)-3-pyridin-3-ylbutanoate Chemical compound C=1C=CN=CC=1C(C)(CC(=O)OCC)CC1=CC=C(C)C=C1 OPLFCBAQVUFSJL-UHFFFAOYSA-N 0.000 description 1
• YWWFGIHGVBJPSP-UHFFFAOYSA-N ethyl 3-methyl-4-oxo-4-(4-phenylmethoxyphenyl)butanoate Chemical compound C1=CC(C(=O)C(C)CC(=O)OCC)=CC=C1OCC1=CC=CC=C1 YWWFGIHGVBJPSP-UHFFFAOYSA-N 0.000 description 1
• UJCTWFUGVGTASJ-UHFFFAOYSA-N ethyl 4-(2,5-dibromo-4-hydroxy-3-methoxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC(Br)=C(O)C(OC)=C1Br UJCTWFUGVGTASJ-UHFFFAOYSA-N 0.000 description 1
• SUBMZEFJOFHKCK-UHFFFAOYSA-N ethyl 4-(2-bromo-4-hydroxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC=C(O)C=C1Br SUBMZEFJOFHKCK-UHFFFAOYSA-N 0.000 description 1
• CIRXKAXWJVVVNA-UHFFFAOYSA-N ethyl 4-(2-bromo-4-methoxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC=C(OC)C=C1Br CIRXKAXWJVVVNA-UHFFFAOYSA-N 0.000 description 1
• FEKQYCWBJMZOPY-UHFFFAOYSA-N ethyl 4-(3-bromo-5-fluoro-4-hydroxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC(F)=C(O)C(Br)=C1 FEKQYCWBJMZOPY-UHFFFAOYSA-N 0.000 description 1
• ZEUHDGYZKRELHJ-UHFFFAOYSA-N ethyl 4-(3-fluoro-4-hydroxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC=C(O)C(F)=C1 ZEUHDGYZKRELHJ-UHFFFAOYSA-N 0.000 description 1
• FAGIAYCBUSQNEV-UHFFFAOYSA-N ethyl 4-(4-hydroxy-3-methoxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC=C(O)C(OC)=C1 FAGIAYCBUSQNEV-UHFFFAOYSA-N 0.000 description 1
• JBDUNAUCDYVWHT-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenyl)-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC=C(O)C=C1 JBDUNAUCDYVWHT-UHFFFAOYSA-N 0.000 description 1
• WKKWGVPVTBNYMU-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenyl)-3-methyl-3-pyridin-3-ylbutanoate Chemical compound C=1C=CN=CC=1C(C)(CC(=O)OCC)CC1=CC=C(O)C=C1 WKKWGVPVTBNYMU-UHFFFAOYSA-N 0.000 description 1
• NRFVFTQGZIDTNA-UHFFFAOYSA-N ethyl 4-[2-cyano-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoate Chemical compound C1=C(C#N)C(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=N1 NRFVFTQGZIDTNA-UHFFFAOYSA-N 0.000 description 1
• FOZRMTKZMWONBT-UHFFFAOYSA-N ethyl 4-[3-bromo-5-fluoro-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoate Chemical compound BrC1=CC(CC(C)(C)CC(=O)OCC)=CC(F)=C1OCCCNC1=CC=CC=N1 FOZRMTKZMWONBT-UHFFFAOYSA-N 0.000 description 1
• DLLCMRVUAKEQSR-UHFFFAOYSA-N ethyl 4-[3-fluoro-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoate Chemical compound FC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=N1 DLLCMRVUAKEQSR-UHFFFAOYSA-N 0.000 description 1
• DXFJKSZFSNUHSE-UHFFFAOYSA-N ethyl 4-[3-methoxy-4-[3-(pyridin-2-ylamino)propoxy]phenyl]-3,3-dimethylbutanoate Chemical compound COC1=CC(CC(C)(C)CC(=O)OCC)=CC=C1OCCCNC1=CC=CC=N1 DXFJKSZFSNUHSE-UHFFFAOYSA-N 0.000 description 1
• VYGRJVZTDJSYNX-UHFFFAOYSA-N ethyl 4-[4-(3-aminopropoxy)-3-bromo-5-fluorophenyl]-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)CC1=CC(F)=C(OCCCN)C(Br)=C1 VYGRJVZTDJSYNX-UHFFFAOYSA-N 0.000 description 1
• 239000002024 ethyl acetate extract Substances 0.000 description 1
• OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229940009626 etidronate Drugs 0.000 description 1
• 229940065639 etoposide 100 mg Drugs 0.000 description 1
• 238000010265 fast atom bombardment Methods 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229940110363 floxuridine 500 mg Drugs 0.000 description 1
• 229940116447 fludarabine phosphate 50 mg Drugs 0.000 description 1
• 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 229940002989 goserelin 3.6 mg Drugs 0.000 description 1
• 229960003607 granisetron hydrochloride Drugs 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 1
• 125000004995 haloalkylthio group Chemical group 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960002293 leucovorin calcium Drugs 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
• QGEFGPVWRJCFQP-UHFFFAOYSA-M magnesium;methanidylbenzene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C1=CC=CC=C1 QGEFGPVWRJCFQP-UHFFFAOYSA-M 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
• MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
• FVIDFFAUVZBSSW-UHFFFAOYSA-N methyl 3,3-dimethyl-4-[4-[2-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-2-yl]ethoxy]phenyl]butanoate Chemical compound C1=CC(CC(C)(C)CC(=O)OC)=CC=C1OCCC1=CC=CC(NC(=O)OC(C)(C)C)=N1 FVIDFFAUVZBSSW-UHFFFAOYSA-N 0.000 description 1
• ZUONBYGWIXQCAN-UHFFFAOYSA-N methyl 3,3-dimethyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoate Chemical compound C1=CC(CC(C)(C)CC(=O)OC)=CC=C1OCCCNC1=CC=CC=N1 ZUONBYGWIXQCAN-UHFFFAOYSA-N 0.000 description 1
• REAWVUWREPGDQS-UHFFFAOYSA-N methyl 3,3-dimethyl-4-oxo-4-(4-phenylmethoxyphenyl)butanoate Chemical compound C1=CC(C(=O)C(C)(C)CC(=O)OC)=CC=C1OCC1=CC=CC=C1 REAWVUWREPGDQS-UHFFFAOYSA-N 0.000 description 1
• BHGSCPALBAKDMR-UHFFFAOYSA-N methyl 4-(4-hydroxyphenyl)-3,3-dimethylbutanoate Chemical compound COC(=O)CC(C)(C)CC1=CC=C(O)C=C1 BHGSCPALBAKDMR-UHFFFAOYSA-N 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
• 150000002905 orthoesters Chemical class 0.000 description 1
• 230000001599 osteoclastic effect Effects 0.000 description 1
• 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
• 229960003978 pamidronic acid Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960001744 pegaspargase Drugs 0.000 description 1
• 108010001564 pegaspargase Proteins 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000019612 pigmentation Effects 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
• 239000012286 potassium permanganate Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229940116357 potassium thiocyanate Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical class CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 230000009295 sperm incapacitation Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• OKYNJCQBCZZCET-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-3-[(4-methylphenyl)methyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1CC1(CO)CN(C(=O)OC(C)(C)C)CCC1 OKYNJCQBCZZCET-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
• XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
• XSVAARVWQDEAEL-UHFFFAOYSA-N tert-butyl n-(6-methylpyridin-2-yl)carbamate Chemical compound CC1=CC=CC(NC(=O)OC(C)(C)C)=N1 XSVAARVWQDEAEL-UHFFFAOYSA-N 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 229940089635 thiotepa 15 mg Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
• 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
• 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1